Loading…
Loading…
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the third quarter 2026, which will be.
Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Institutional and Insider Ownership 77.4% of Organon
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
VANCOUVER, BC / ACCESS Newswire / October 13, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement (the "Agreement") with a subsidiary of Seabridge Gold Inc. ("Seabridge") whereby Seabridge will acquire a 100% interest in Orogen's Slaughterhouse Iron-Oxide-Copper-Gold ("IOCG") project in Wyoming, USA. Under the terms of the Agreement, Seabridge will pay to Orogen US$300,000 cash on closing and milestone payments of up to US$2.55 million.
VANCOUVER, BC / ACCESS Newswire / October 8, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement (the "Agreement") with Northern Discovery Metals (CSE:NOR) ("Northern") whereby Northern will acquire a 100% interest in the Cibola copper-gold porphyry project in British Columbia, Canada. Under the terms of the Agreement, Northern will pay to Orogen $130,000 and issue 700,000 common shares of Northern.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.